REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md., Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44^th Annual J.P. Morgan Healthcare Conference.

Presentation Details
Date and Time: Wednesday, January 14, 2026 at 10:30 a.m. PT
Location: Westin St. Francis, San Francisco, CA

A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
[email protected] 

Investors:
George E. MacDougall
Investor Relations
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302645444.html

SOURCE REGENXBIO Inc.